Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19025000 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2CYP2C19PDE4BGRIN2BNPC1 | |
| SCHEMBL29895888 | 0.91 | PDE4B (0.44) | SMN1; SMN2CYP2C19PDE4BGRIN2BNPC1 | |
| SCHEMBL28827679 | 0.91 | PDE4B (0.44) | SMN1; SMN2CYP2C19PDE4BGRIN2BNPC1 | |
| SCHEMBL17121774 | 0.91 | PDE4B (0.44) | SMN1; SMN2CYP2C19PDE4BGRIN2BNPC1 | |
| SCHEMBL19025015 | 0.81 | EGFR (0.57) | PDE4BCYP2D6CYP2C9STING1 | |
| SCHEMBL19025016 | 0.81 | EGFR (0.57) | PDE4BCYP2D6CYP2C9STING1 | |
| SCHEMBL18681346 | 0.77 | KDM1A (0.44) | PDE4B | |
| SCHEMBL30557861 | 0.76 | PDE4B (0.47) | SMN1; SMN2CYP2C19PDE4BGRIN2BNPC1 | |
| SCHEMBL18669405 | 0.76 | PDE4B (0.47) | SMN1; SMN2CYP2C19PDE4BGRIN2BNPC1 | |
| SCHEMBL18669424 | 0.76 | PDE4B (0.47) | SMN1; SMN2CYP2C19PDE4BGRIN2BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CAPELLA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| EP-3922630-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Capella Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3119762-B9 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS INC (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3119762-B1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20200291007-A1 | BENZIMIDAZOLE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CAPELLA THERAPEUTICS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20200216419-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2020-07-09 | — | — | US | disclosed |
| US-10647707-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10590108-B2 | Benzimidazoles for use in the treatment of cancer and inflammatory diseases | CAPELLA THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20180291012-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS INC (US) | 2018-10-11 | — | — | US | disclosed |
| US-20180273511-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2018-09-27 | — | — | US | disclosed |
| US-10005765-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170183330-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273511-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CHKB, CHKA, CHUK | SMN1; SMN2 4365/4885CYP2C19 474/4885PDE4B 1750/4885 |
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CCNI, CYP2C19, PHB1 | SMN1; SMN2 2199/4885CYP2C19 2/4885PDE4B 933/4885 |
| US-20200216419-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CHKB, CHKA, CHUK | SMN1; SMN2 4365/4885CYP2C19 474/4885PDE4B 1750/4885 |
| US-10647707-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | ERBB2, ERBB4, ERBB3 | SMN1; SMN2 4744/4885CYP2C19 657/4885PDE4B 3021/4885 |
| US-20170183330-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | SMN1; SMN2 4744/4885CYP2C19 657/4885PDE4B 3021/4885 |
| US-10590108-B2 | Benzimidazoles for use in the treatment of cancer and inflammatory diseases | CHKB, CHKA, CHUK | SMN1; SMN2 4365/4885CYP2C19 474/4885PDE4B 1750/4885 |
| US-10005765-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | ERBB2, ERBB4, ERBB3 | SMN1; SMN2 4744/4885CYP2C19 657/4885PDE4B 3021/4885 |
| US-20180291012-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | SMN1; SMN2 4744/4885CYP2C19 657/4885PDE4B 3021/4885 |
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CHKB, CHKA, CHUK | SMN1; SMN2 4365/4885CYP2C19 474/4885PDE4B 1750/4885 |
| US-20200291007-A1 | BENZIMIDAZOLE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CCNI, CYP2C19, PHB1 | SMN1; SMN2 2199/4885CYP2C19 2/4885PDE4B 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.